Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD)
relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with
different doses of ACZ885 and to evaluate the impact of the subcutaneous (s.c.) versus
intravenous (i.v.) route of administration.